These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24488851)

  • 21. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.
    Jüptner M; Zeuner R; Schreiber S; Laudes M; Schröder JO
    Lupus; 2014 Apr; 23(4):428-30. PubMed ID: 24482144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab.
    Umeda M; Kojima K; Michitsuji T; Tsuji Y; Shimizu T; Fukui S; Sumiyoshi R; Koga T; Kawashiri SY; Naoki I; Iagawa T; Tamai M; Origuchi T; Furuyama M; Tsuboi M; Matsuoka N; Okada A; Aramaki T; Kawakami A
    Mod Rheumatol; 2024 Oct; 34(6):1281-1283. PubMed ID: 38756072
    [No Abstract]   [Full Text] [Related]  

  • 23. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
    Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
    Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus.
    Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
    Ann Rheum Dis; 2020 Feb; 79(2):304-307. PubMed ID: 31712248
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
    Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
    Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
    Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
    Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience.
    Fredi M; Vojinovic T; Regola F; Babaglioni G; Bettoni D; Andreoli L; Tincani A; Franceschini F
    Rheumatology (Oxford); 2023 Feb; 62(2):e18-e20. PubMed ID: 35946521
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
    Simonetta F; Allali D; Roux-Lombard P; Chizzolini C
    Joint Bone Spine; 2017 Mar; 84(2):235-236. PubMed ID: 27238199
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
    Sthoeger Z; Lorber M; Tal Y; Toubi E; Amital H; Kivity S; Langevitz P; Asher I; Elbirt D; Agmon Levin N
    Isr Med Assoc J; 2017 Jan; 19(1):44-48. PubMed ID: 28457114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open-label study.
    Sandhu VK; Wallace DJ; Weisman MH
    J Rheumatol; 2015 Apr; 42(4):728-30. PubMed ID: 25834243
    [No Abstract]   [Full Text] [Related]  

  • 33. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET-CT scan to diagnose and demonstrate resolution of lupus lymphadenitis with belimumab.
    Garcia-Cirera S; Calvet J; Martin-Marimon JC; García-Chamón RB; Gratacós J
    Rheumatology (Oxford); 2021 Sep; 60(9):e324-e325. PubMed ID: 33693531
    [No Abstract]   [Full Text] [Related]  

  • 36. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
    van Vollenhoven RF; Petri M; Wallace DJ; Roth DA; Molta CT; Hammer AE; Tang Y; Thompson A
    Arthritis Rheumatol; 2016 Sep; 68(9):2184-92. PubMed ID: 26992106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on belimumab for the management of systemic lupus erythematosus.
    Lutalo PM; D'Cruz DP
    Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus.
    Hashimoto S; Fujita M; Aizawa T; Watanabe S; Tsugawa K; Tanaka H
    Lupus; 2024 Apr; 33(5):543-544. PubMed ID: 38456833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.